Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23431160 | 0.84 | TSHR (0.52) | TSHRRORCALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL10120401 | 0.82 | TSHR (0.53) | TSHRRORC | |
| SCHEMBL30270585 | 0.82 | TSHR (0.53) | TSHRRORC | |
| SCHEMBL10553075 | 0.81 | CA2 (0.55) | TSHRRORCALDH1A1TDP1CYP3A4 | |
| SCHEMBL1313842 | 0.81 | TSHR (0.48) | TSHRRORCALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL28562630 | 0.81 | TSHR (0.47) | TSHRALDH1A1TDP1CYP3A4CYP2C19 | |
| SCHEMBL6428005 | 0.81 | TSHR (0.49) | TSHRRORCALDH1A1TDP1CYP3A4 | |
| SCHEMBL29290994 | 0.80 | ALDH1A1 (0.39) | TSHRALDH1A1TDP1CYP3A4CYP2C19 | |
| SCHEMBL1042165 | 0.79 | TSHR (0.47) | TSHRRORCALDH1A1TDP1CYP3A4 | |
| SCHEMBL994607 | 0.79 | TSHR (0.73) | TSHRRORCKDM4EL3MBTL1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008495-A1 | NOVEL COMPOUNDS AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2 | UNIV PARIS (FR) | 2023-01-12 | — | — | US | disclosed |
| US-20220220112-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008495-A1 | NOVEL COMPOUNDS AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2 | CASP2, CASP1, CASP5 | TSHR 4727/4885RORC 4573/4885ALDH1A1 2295/4885 |
| US-20220220112-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | TSHR 4245/4885RORC 2221/4885ALDH1A1 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.